vs
ADAMAS TRUST, INC.（ADAM）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
ADAMAS TRUST, INC.的季度营收约是REGENXBIO Inc.的1.4倍（$43.2M vs $30.3M），ADAMAS TRUST, INC.净利率更高（124.0% vs -221.3%，领先345.3%），ADAMAS TRUST, INC.同比增速更快（61.6% vs 43.0%），ADAMAS TRUST, INC.自由现金流更多（$125.9M vs $-52.8M），过去两年ADAMAS TRUST, INC.的营收复合增速更高（55.5% vs 39.4%）
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
ADAM vs RGNX — 直观对比
营收规模更大
ADAM
是对方的1.4倍
$30.3M
营收增速更快
ADAM
高出18.6%
43.0%
净利率更高
ADAM
高出345.3%
-221.3%
自由现金流更多
ADAM
多$178.7M
$-52.8M
两年增速更快
ADAM
近两年复合增速
39.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $43.2M | $30.3M |
| 净利润 | $53.5M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | — | -190.0% |
| 净利率 | 124.0% | -221.3% |
| 营收同比 | 61.6% | 43.0% |
| 净利润同比 | 270.5% | -31.2% |
| 每股收益（稀释后） | $0.45 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADAMRGNX
| Q4 25 | $43.2M | $30.3M | ||
| Q3 25 | $36.6M | $29.7M | ||
| Q2 25 | $36.4M | $21.4M | ||
| Q1 25 | $33.1M | $89.0M | ||
| Q4 24 | $26.7M | $21.2M | ||
| Q3 24 | $20.2M | $24.2M | ||
| Q2 24 | $19.0M | $22.3M | ||
| Q1 24 | $17.9M | $15.6M |
净利润ADAMRGNX
| Q4 25 | $53.5M | $-67.1M | ||
| Q3 25 | $44.8M | $-61.9M | ||
| Q2 25 | $8.5M | $-70.9M | ||
| Q1 25 | $42.2M | $6.1M | ||
| Q4 24 | $-31.4M | $-51.2M | ||
| Q3 24 | $42.8M | $-59.6M | ||
| Q2 24 | $-15.6M | $-53.0M | ||
| Q1 24 | $-57.9M | $-63.3M |
毛利率ADAMRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率ADAMRGNX
| Q4 25 | — | -190.0% | ||
| Q3 25 | — | -176.3% | ||
| Q2 25 | 11.7% | -296.3% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | -119.0% | -242.1% | ||
| Q3 24 | — | -256.6% | ||
| Q2 24 | -124.7% | -251.3% | ||
| Q1 24 | -448.8% | -408.8% |
净利率ADAMRGNX
| Q4 25 | 124.0% | -221.3% | ||
| Q3 25 | 122.5% | -208.3% | ||
| Q2 25 | 23.4% | -331.8% | ||
| Q1 25 | 127.4% | 6.8% | ||
| Q4 24 | -117.5% | -241.3% | ||
| Q3 24 | 211.7% | -246.3% | ||
| Q2 24 | -81.9% | -237.7% | ||
| Q1 24 | -324.1% | -405.4% |
每股收益（稀释后）ADAMRGNX
| Q4 25 | $0.45 | $-1.30 | ||
| Q3 25 | $0.36 | $-1.20 | ||
| Q2 25 | $-0.04 | $-1.38 | ||
| Q1 25 | $0.33 | $0.12 | ||
| Q4 24 | $-0.46 | $-0.99 | ||
| Q3 24 | $0.36 | $-1.17 | ||
| Q2 24 | $-0.29 | $-1.05 | ||
| Q1 24 | $-0.75 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $210.3M | $230.1M |
| 总债务越低越好 | $735.8M | — |
| 股东权益账面价值 | $1.4B | $102.7M |
| 总资产 | $12.6B | $453.0M |
| 负债/权益比越低杠杆越低 | 0.52× | — |
8季度趋势，按日历期对齐
现金及短期投资ADAMRGNX
| Q4 25 | $210.3M | $230.1M | ||
| Q3 25 | $185.3M | $274.2M | ||
| Q2 25 | $160.4M | $323.3M | ||
| Q1 25 | $177.1M | $267.9M | ||
| Q4 24 | $167.4M | $234.7M | ||
| Q3 24 | $195.1M | $255.5M | ||
| Q2 24 | $235.5M | $290.4M | ||
| Q1 24 | $226.9M | $338.7M |
总债务ADAMRGNX
| Q4 25 | $735.8M | — | ||
| Q3 25 | $766.6M | — | ||
| Q2 25 | $653.0M | — | ||
| Q1 25 | $654.4M | — | ||
| Q4 24 | $573.2M | — | ||
| Q3 24 | $699.4M | — | ||
| Q2 24 | $800.7M | — | ||
| Q1 24 | $1.0B | — |
股东权益ADAMRGNX
| Q4 25 | $1.4B | $102.7M | ||
| Q3 25 | $1.4B | $161.5M | ||
| Q2 25 | $1.4B | $213.7M | ||
| Q1 25 | $1.4B | $274.2M | ||
| Q4 24 | $1.4B | $259.7M | ||
| Q3 24 | $1.4B | $301.4M | ||
| Q2 24 | $1.4B | $348.3M | ||
| Q1 24 | $1.5B | $390.7M |
总资产ADAMRGNX
| Q4 25 | $12.6B | $453.0M | ||
| Q3 25 | $12.4B | $525.2M | ||
| Q2 25 | $10.6B | $581.0M | ||
| Q1 25 | $10.0B | $490.9M | ||
| Q4 24 | $9.2B | $466.0M | ||
| Q3 24 | $8.9B | $519.1M | ||
| Q2 24 | $8.2B | $569.4M | ||
| Q1 24 | $7.4B | $629.2M |
负债/权益比ADAMRGNX
| Q4 25 | 0.52× | — | ||
| Q3 25 | 0.55× | — | ||
| Q2 25 | 0.47× | — | ||
| Q1 25 | 0.47× | — | ||
| Q4 24 | 0.41× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.56× | — | ||
| Q1 24 | 0.67× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $134.0M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $125.9M | $-52.8M |
| 自由现金流率自由现金流/营收 | 291.6% | -174.0% |
| 资本支出强度资本支出/营收 | 18.9% | 1.7% |
| 现金转化率经营现金流/净利润 | 2.50× | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流ADAMRGNX
| Q4 25 | $134.0M | $-52.3M | ||
| Q3 25 | $6.9M | $-56.0M | ||
| Q2 25 | $39.2M | $-49.3M | ||
| Q1 25 | $25.8M | $33.6M | ||
| Q4 24 | $14.1M | $-31.6M | ||
| Q3 24 | $-922.0K | $-40.5M | ||
| Q2 24 | $-993.0K | $-45.5M | ||
| Q1 24 | $-13.1M | $-55.5M |
自由现金流ADAMRGNX
| Q4 25 | $125.9M | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | $-10.6M | $-32.7M | ||
| Q3 24 | $-8.6M | $-40.9M | ||
| Q2 24 | $-8.6M | $-46.0M | ||
| Q1 24 | $-19.1M | $-56.0M |
自由现金流率ADAMRGNX
| Q4 25 | 291.6% | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | -39.6% | -154.2% | ||
| Q3 24 | -42.3% | -168.9% | ||
| Q2 24 | -44.9% | -206.2% | ||
| Q1 24 | -107.0% | -358.5% |
资本支出强度ADAMRGNX
| Q4 25 | 18.9% | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | 92.3% | 5.1% | ||
| Q3 24 | 37.7% | 1.3% | ||
| Q2 24 | 39.7% | 2.1% | ||
| Q1 24 | 33.5% | 3.6% |
现金转化率ADAMRGNX
| Q4 25 | 2.50× | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 4.59× | — | ||
| Q1 25 | 0.61× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.02× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADAM
| Other | $19.6M | 45% |
| Constructive Loans LLC | $14.4M | 33% |
| Multifamily | $9.1M | 21% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
